ESC Professional Premium Access

The real-world safety profile of SGLT2 inhibitors among adults 75 years or older: a retrospective, pharmacovigilance study

Congress Presentation

About the speaker

Associate Professor Elad Maor

Sheba Medical Center, Tel Aviv (Israel)
0 follower

3 more presentations in this session

Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF

Speaker: Doctor C. Adamson (Glasgow, GB)


Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial

Speaker: Doctor A. Pandey (Dallas, US)


Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF

Speaker: Doctor K. Docherty (Glasgow, GB)


Access the full session

SGLT2 inhibitors: pearls from recent trials and surveys

Speakers: Associate Professor E. Maor, Doctor C. Adamson, Doctor A. Pandey, Doctor K. Docherty

About the event


ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb